154 related articles for article (PubMed ID: 37302031)
1. White Matter Hyperintensity Volume and Amyloid-PET Synergistically Impact Memory Independent of Tau-PET in Older Adults Without Dementia.
Edwards L; Thomas KR; Weigand AJ; Edmonds EC; Clark AL; Walker KS; Brenner EK; Nation DA; Maillard P; Bondi MW; Bangen KJ;
J Alzheimers Dis; 2023; 94(2):695-707. PubMed ID: 37302031
[TBL] [Abstract][Full Text] [Related]
2. Association between brain amyloid deposition and longitudinal changes of white matter hyperintensities.
Cha WJ; Yi D; Ahn H; Byun MS; Chang YY; Choi JM; Kim K; Choi H; Jung G; Kang KM; Sohn CH; Lee YS; Kim YK; Lee DY
Alzheimers Res Ther; 2024 Mar; 16(1):50. PubMed ID: 38454444
[TBL] [Abstract][Full Text] [Related]
3. Regional White Matter Hyperintensities and Alzheimer's Disease Biomarkers Among Older Adults with Normal Cognition and Mild Cognitive Impairment.
Newton P; Tchounguen J; Pettigrew C; Lim C; Lin Z; Lu H; Moghekar A; Albert M; Soldan A;
J Alzheimers Dis; 2023; 92(1):323-339. PubMed ID: 36744337
[TBL] [Abstract][Full Text] [Related]
4. Vascular burden and cognition: Mediating roles of neurodegeneration and amyloid PET.
Ottoy J; Ozzoude M; Zukotynski K; Adamo S; Scott C; Gaudet V; Ramirez J; Swardfager W; Cogo-Moreira H; Lam B; Bhan A; Mojiri P; Kang MS; Rabin JS; Kiss A; Strother S; Bocti C; Borrie M; Chertkow H; Frayne R; Hsiung R; Laforce RJ; Noseworthy MD; Prato FS; Sahlas DJ; Smith EE; Kuo PH; Sossi V; Thiel A; Soucy JP; Tardif JC; Black SE; Goubran M;
Alzheimers Dement; 2023 Apr; 19(4):1503-1517. PubMed ID: 36047604
[TBL] [Abstract][Full Text] [Related]
5. White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment.
Guzman VA; Carmichael OT; Schwarz C; Tosto G; Zimmerman ME; Brickman AM;
Alzheimers Dement; 2013 Oct; 9(5 Suppl):S124-31. PubMed ID: 23375566
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal Relationships of White Matter Hyperintensities and Alzheimer Disease Biomarkers Across the Adult Life Span.
Luo J; Ma Y; Agboola FJ; Grant E; Morris JC; McDade E; Fagan AM; Benzinger TLS; Hassenstab J; Bateman RJ; Perrin RJ; Gordon BA; Goyal M; Strain JF; Yakushev I; Day GS; Xiong C;
Neurology; 2023 Jul; 101(2):e164-e177. PubMed ID: 37202169
[TBL] [Abstract][Full Text] [Related]
7. Linking white matter hyperintensities to regional cortical thinning, amyloid deposition, and synaptic density loss in Alzheimer's disease.
Zhang J; Chen H; Wang J; Huang Q; Xu X; Wang W; Xu W; Guan Y; Liu J; Wardlaw JM; Deng Y; Xie F; Li B
Alzheimers Dement; 2024 Jun; 20(6):3931-3942. PubMed ID: 38648354
[TBL] [Abstract][Full Text] [Related]
8. Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline.
Bos I; Verhey FR; Ramakers IHGB; Jacobs HIL; Soininen H; Freund-Levi Y; Hampel H; Tsolaki M; Wallin ÅK; van Buchem MA; Oleksik A; Verbeek MM; Olde Rikkert M; van der Flier WM; Scheltens P; Aalten P; Visser PJ; Vos SJB
Alzheimers Res Ther; 2017 Dec; 9(1):101. PubMed ID: 29284531
[TBL] [Abstract][Full Text] [Related]
9. White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease.
Soldan A; Pettigrew C; Zhu Y; Wang MC; Moghekar A; Gottesman RF; Singh B; Martinez O; Fletcher E; DeCarli C; Albert M;
Neurology; 2020 Mar; 94(9):e950-e960. PubMed ID: 31888969
[TBL] [Abstract][Full Text] [Related]
10. White matter hyperintensities and cognition across different Alzheimer's biomarker profiles.
Lam S; Lipton RB; Harvey DJ; Zammit AR; Ezzati A;
J Am Geriatr Soc; 2021 Jul; 69(7):1906-1915. PubMed ID: 33891712
[TBL] [Abstract][Full Text] [Related]
11. Neuroinflammation and amyloid deposition in the progression of mixed Alzheimer and vascular dementia.
Ying C; Kang P; Binkley MM; Ford AL; Chen Y; Hassenstab J; Wang Q; Strain J; Morris JC; Lee JM; Benzinger TLS; An H
Neuroimage Clin; 2023; 38():103373. PubMed ID: 36933348
[TBL] [Abstract][Full Text] [Related]
12. White matter hyperintensities are higher among early-onset Alzheimer's disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer's Disease Study (LEADS).
Eloyan A; Thangarajah M; An N; Borowski BJ; Reddy AL; Aisen P; Dage JL; Foroud T; Ghetti B; Griffin P; Hammers D; Iaccarino L; Jack CR; Kirby K; Kramer J; Koeppe R; Kukull WA; La Joie R; Mundada NS; Murray ME; Nudelman K; Rumbaugh M; Soleimani-Meigooni DN; Toga A; Touroutoglou A; Atri A; Day GS; Duara R; Graff-Radford NR; Honig LS; Jones DT; Masdeu J; Mendez MF; Musiek E; Onyike CU; Rogalski E; Salloway S; Sha S; Turner RS; Wingo TS; Wolk DA; Womack K; Beckett L; Gao S; Carrillo MC; Rabinovici G; Apostolova LG; Dickerson B; Vemuri P;
Alzheimers Dement; 2023 Nov; 19 Suppl 9(Suppl 9):S89-S97. PubMed ID: 37491599
[TBL] [Abstract][Full Text] [Related]
13. CSF amyloid is a consistent predictor of white matter hyperintensities across the disease course from aging to Alzheimer's disease.
Walsh P; Sudre CH; Fiford CM; Ryan NS; Lashley T; Frost C; Barnes J;
Neurobiol Aging; 2020 Jul; 91():5-14. PubMed ID: 32305782
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer-Related Cerebrovascular Disease in Down Syndrome.
Lao PJ; Gutierrez J; Keator D; Rizvi B; Banerjee A; Igwe KC; Laing KK; Sathishkumar M; Moni F; Andrews H; Krinsky-McHale S; Head E; Lee JH; Lai F; Yassa MA; Rosas HD; Silverman W; Lott IT; Schupf N; Brickman AM
Ann Neurol; 2020 Dec; 88(6):1165-1177. PubMed ID: 32944999
[TBL] [Abstract][Full Text] [Related]
15. White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition.
Raghavan S; Przybelski SA; Reid RI; Lesnick TG; Ramanan VK; Botha H; Matchett BJ; Murray ME; Reichard RR; Knopman DS; Graff-Radford J; Jones DT; Lowe VJ; Mielke MM; Machulda MM; Petersen RC; Kantarci K; Whitwell JL; Josephs KA; Jack CR; Vemuri P
Acta Neuropathol Commun; 2022 Feb; 10(1):16. PubMed ID: 35123591
[TBL] [Abstract][Full Text] [Related]
16. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.
Maass A; Landau S; Baker SL; Horng A; Lockhart SN; La Joie R; Rabinovici GD; Jagust WJ;
Neuroimage; 2017 Aug; 157():448-463. PubMed ID: 28587897
[TBL] [Abstract][Full Text] [Related]
17. White Matter Hyperintensity as a Vascular Contribution to the AT(N) Framework.
Ng KP; Shen JY; Chiew HJ; Ng ASL; Kandiah N; Rosa-Neto P; Gauthier S
J Prev Alzheimers Dis; 2023; 10(3):387-400. PubMed ID: 37357280
[TBL] [Abstract][Full Text] [Related]
18. The association between white matter hyperintensities and amyloid and tau deposition.
Alban SL; Lynch KM; Ringman JM; Toga AW; Chui HC; Sepehrband F; Choupan J;
Neuroimage Clin; 2023; 38():103383. PubMed ID: 36965457
[TBL] [Abstract][Full Text] [Related]
19. Age, vascular disease, and Alzheimer's disease pathologies in amyloid negative elderly adults.
Guo T; Landau SM; Jagust WJ;
Alzheimers Res Ther; 2021 Oct; 13(1):174. PubMed ID: 34654465
[TBL] [Abstract][Full Text] [Related]
20. Brain amyloid burden and cerebrovascular disease are synergistically associated with neurometabolism in cognitively unimpaired older adults.
Schreiner SJ; Kirchner T; Narkhede A; Wyss M; Van Bergen JMG; Steininger SC; Gietl A; Leh SE; Treyer V; Buck A; Pruessmann KP; Nitsch RM; Hock C; Henning A; Brickman AM; Unschuld PG
Neurobiol Aging; 2018 Mar; 63():152-161. PubMed ID: 29310864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
